[{"address1": "12278 Scripps Summit Drive", "city": "San Diego", "state": "CA", "zip": "92131", "country": "United States", "phone": "858 875 1800", "website": "https://www.fatetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bahram  Valamehr M.B.A., Ph.D.", "age": 47, "title": "President, CEO & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 676600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cindy R. Tahl J.D.", "age": 51, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 644600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamal  Adawi M.S., MBA", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Francis", "title": "Vice President Of Human Resources & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Victor  Hong", "title": "Vice President of Corporate Development & Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Henry", "age": 60, "title": "Senior Vice President of Clinical Operations", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tunde  Babalola Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yu  Cai J.D., Ph.D.", "title": "Head of Intellectual Property & Assistant General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kate  Duvall", "title": "Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 10, "overallRisk": 7, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.04, "open": 1.025, "dayLow": 1.0, "dayHigh": 1.1, "regularMarketPreviousClose": 1.04, "regularMarketOpen": 1.025, "regularMarketDayLow": 1.0, "regularMarketDayHigh": 1.1, "payoutRatio": 0.0, "beta": 2.336, "forwardPE": -0.63690484, "volume": 1650889, "regularMarketVolume": 1650889, "averageVolume": 2205280, "averageVolume10days": 2803480, "averageDailyVolume10Day": 2803480, "bid": 1.07, "ask": 1.11, "bidSize": 16, "askSize": 27, "marketCap": 123402784, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.5, "allTimeHigh": 121.16, "allTimeLow": 0.66, "priceToSalesTrailing12Months": 14.569396, "fiftyDayAverage": 1.2218, "twoHundredDayAverage": 1.166, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -18093224, "profitMargins": 0.0, "floatShares": 100797002, "sharesOutstanding": 115329697, "sharesShort": 7544331, "sharesShortPriorMonth": 9877527, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0654, "heldPercentInsiders": 0.01771, "heldPercentInstitutions": 0.7886, "shortRatio": 2.65, "shortPercentOfFloat": 0.0746, "impliedSharesOutstanding": 115329697, "bookValue": 2.28, "priceToBook": 0.46929827, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -171522000, "trailingEps": -1.46, "forwardEps": -1.68, "enterpriseToRevenue": -2.136, "enterpriseToEbitda": 0.112, "52WeekChange": -0.59375, "SandP52WeekChange": 0.1198014, "quoteType": "EQUITY", "currentPrice": 1.07, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.94444, "targetMedianPrice": 5.0, "recommendationMean": 2.16667, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 222830000, "totalCashPerShare": 1.932, "ebitda": -161604992, "totalDebt": 81331000, "quickRatio": 7.89, "currentRatio": 8.035, "totalRevenue": 8470000, "debtToEquity": 31.118, "revenuePerShare": 0.072, "returnOnAssets": -0.24659, "returnOnEquity": -0.52107, "grossProfits": -106806000, "freeCashflow": -60912500, "operatingCashflow": -115614000, "revenueGrowth": -0.718, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -19.38542, "financialCurrency": "USD", "symbol": "FATE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Fate Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1380634200000, "postMarketChangePercent": 0.9345785, "postMarketPrice": 1.08, "postMarketChange": 0.00999999, "regularMarketChange": 0.0300001, "regularMarketDayRange": "1.0 - 1.1", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2205280, "fiftyTwoWeekLowChange": 0.41000003, "fiftyTwoWeekLowChangePercent": 0.6212121, "fiftyTwoWeekRange": "0.66 - 3.5", "fiftyTwoWeekHighChange": -2.4299998, "fiftyTwoWeekHighChangePercent": -0.6942857, "fiftyTwoWeekChangePercent": -59.375, "earningsTimestampStart": 1762894800, "earningsTimestampEnd": 1762894800, "earningsCallTimestampStart": 1715288400, "earningsCallTimestampEnd": 1715288400, "isEarningsDateEstimate": true, "corporateActions": [], "postMarketTime": 1762560943, "regularMarketTime": 1762549200, "exchange": "NGM", "messageBoardId": "finmb_39268712", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "longName": "Fate Therapeutics, Inc.", "regularMarketChangePercent": 2.88462, "regularMarketPrice": 1.07, "epsTrailingTwelveMonths": -1.46, "epsForward": -1.68, "epsCurrentYear": -1.13556, "priceEpsCurrentYear": -0.9422664, "fiftyDayAverageChange": -0.15179992, "fiftyDayAverageChangePercent": -0.12424286, "twoHundredDayAverageChange": -0.095999956, "twoHundredDayAverageChangePercent": -0.08233272, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.2 - Buy", "cryptoTradeable": false, "displayName": "Fate Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]